Intas Pharmaceuticals has been granted a patent for an extended release pharmaceutical composition of Clozapine. The composition includes granules of Clozapine, seal coating, acidic coating, and extended release coating, suitable for once-a-day dosing. The ratio of acidic substance to Clozapine is specified in the claim. GlobalData’s report on Intas Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Intas Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Intas Pharmaceuticals's grant share as of January 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11833253B1) discloses an extended-release pharmaceutical composition of Clozapine in the form of multiparticulates. The composition includes granules, pellets, beads, or spheroids containing Clozapine, along with seal coating comprising a hydrophilic polymer, an acidic coating with an acidic substance, and an extended-release coating with a water-insoluble polymer and a water-soluble polymer. The ratio of the acidic substance in the acidic coating to Clozapine is specified within a range, and notably, Clozapine is not coated on a sugar sphere.
Furthermore, the patent details variations in the composition, such as the inclusion of an osmotic agent in the acidic coating and specific materials for the seal coating, acidic coating, and extended-release coating. The patent also outlines the process of coating Clozapine with a seal coat, followed by an acidic coat and an extended-release coat. The multiparticulates can be dispensed or compressed into tablets, mini-tablets, or filled into capsules, providing flexibility in administration methods. Overall, the patent highlights a novel formulation of Clozapine for extended release, offering potential benefits in the treatment of relevant medical conditions.
To know more about GlobalData’s detailed insights on Intas Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
